Auxilium Pharmaceuticals, Inc. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript

Auxilium Pharmaceuticals, Inc. (AUXL) 3Q09 (Qtr End 9/30/09) Earnings Call Transcript October 28, 2009 10:00 ET Executives James E. Fickenscher - Chief Financial Officer Armando Anido - Chief Executive Officer and President Roger D. Graham, Jr. - Executive Vice President, Sales and Marketing Jennifer Evans Stacey - Executive Vice President, General Counsel, Human Resources, and Secretary William Q. Sargent, Jr. - Vice-President, Investor Relations and Corporate Communications Analysts Marshall Urist - Morgan Stanley Salveen Kochnover - Collins Stewart, LLC Eric Schmidt - Cowen and Company John Newman – Oppenheimer & Co. Joseph Schwartz - Leerink Swann Eun Yang - Jefferies & Company Raghuram Selvaraju - Hapoalim Securities Scott Henry - ROTH Capital David Moskowitz - Caris & Company Annabel Samimy - Thomas Weisel Partners LLC Michael Yee - RBC Capital Markets Presentation Operator Good day ladies and gentlemen and welcome to the Third Quarter 2009 Auxilium Pharmaceuticals Incorporated Earnings Conference Call. My name is (ph) Esha and I would be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. (Operator Instructions) I would now like to turn the call over to Mr. William Sargent, Vice President of Investor Relations and Corporate Communications of Auxilium Pharmaceuticals. Please proceed. William Q. Sargent, Jr. Thank you, operator and good morning everyone. With me today are Armando Anido, Chief Executive Officer and President of Auxilium; Jim Fickenscher, Auxilium’s Chief Financial...
Click here to read the whole Article (external link)

Auxilium Pharmaceuticals, Inc. Earnings Call scheduled for 10:00 am ET today

Call DetailsAuxilium Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009)Wed, Oct 28, 2009, 10:00 am EasternAbout Auxilium Pharmaceuticals, Inc. (NasdaqGS:AUXL)Other Calls Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and primary care physicians primarily in the United States. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism. Its product pipeline also includes XIAFLEX, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren’s contracture; and in Phase II of development for the treatment of Peyronie’s Disease and Adhesive Capsulitis. The company’s product pipeline also comprises AA4010, which is in Phase I of development for the treatment of overactive bladder using its transmucosal film delivery system; and A Fentanyl, a pain product, which is in Phase I of development. It has agreement with Pfizer, Inc. for the development, commercialization, and supply of XIAFLEX in European and Eurasian countries. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania.More Info:Quote |Chart |Profile |Reports |Research |Msgs |Insider |Financials | ...
Click here to read the whole Article (external link)

Auxilium Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

MALVERN, PA--(Marketwire - 11/02/09) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL - News) today announced that executive management will participate in the Oppenheimer Healthcare Conference to be held November 3 - 4, 2009 at the Waldorf Astoria in New York City. Mr. Armando Anido, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:50 a.m. EST on Wednesday, November 4, 2009. To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for ninety days after the event.About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim� 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is in phase II...
Click here to read the whole Article (external link)

Auxilium Pharmaceuticals, Inc. (AUXL) Chief Executive Officer and President to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Nov. 3, 2009 (GLOBE NEWSWIRE) -- What: Auxilium Pharmaceuticals, Inc. (AUXL) will visit the NASDAQ MarketSite in New York City's Times Square to mark its five year anniversary on the NASDAQ exchange. In honor of the occasion, Armando Anido, Chief Executive Officer and President of the Company, will preside over the NASDAQ Closing Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday, November 4th 2009 at 3:45 p.m. to 4:00 p.m. ET Contacts: Will Sargent (484) 321-5900 (office) wsargent@auxilium.com Rebekah Sinzheimer (312)729.4239 rsinzheimer@golinharris.com NASDAQ MarketSite: Robert Madden (646) 441-5045 Robert.Madden@NASDAQOMX.com Feed Information: The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045. Radio Feed: An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well. Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/pages/NASDAQ-OMX/108167527653 For news tweet...
Click here to read the whole Article (external link)

AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

Show all filings for AUXILIUM PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for AUXILIUM PHARMACEUTICALS INC 2-Nov-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provi...
Click here to read the whole Article (external link)

Auxilium Pharmaceuticals to Present at the Credit Suisse 18th Annual Global Healthcare Conference

MALVERN, PA--(Marketwire - 11/10/09) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL - News) today announced that executive management will participate in the Credit Suisse Global Healthcare Conference to be held November 11 - 13, 2009 at the Arizona Biltmore in Phoenix, Arizona. Mr. Jim Fickenscher, Chief Financial Officer, is scheduled to present an overview of the Company and its product pipeline at 8:00 a.m. MST on Friday, November 13, 2009. To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for ninety days after the event.About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim� 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is in phase II...
Click here to read the whole Article (external link)

AUXILIUM PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the consolidated financial statements and the notes thereto appearing elsewhere in this report. Special Note Regarding Forward-Looking Statements Certain statements in this quarterly report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements made with respect to our strategy, progress and timing of development programs and related trials, the timing of actions to be taken by regulatory authorities, the efficacy of our product candidates, the commercial benefits available to us as a result of our agreements with third parties, future operations, financial position, future revenues, projected costs, the size of addressable markets, prospects, plans and objectives of management and other statements regarding matters that are not historical facts. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be Table of Contents materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "seem," "seek," "future," "continue," or "appear" or the negative of these terms or similar expressions, although not all ...
Click here to read the whole Article (external link)

Auxilium Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MALVERN, PA--(Marketwire - 11/11/09) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL - News) today announced that executive management will participate in the Lazard Capital Markets Healthcare Conference to be held November 17 - 18, 2009 at The St. Regis Hotel in New York City. Mr. Armando Anido, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30a.m. EST on Wednesday, November 18, 2009. To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for ninety days after the event.About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim� 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is...
Click here to read the whole Article (external link)

AUXILIUM PHARMACEUTICALS INC Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue42,143  39,195  34,674  34,774  Cost of Revenue9,545  9,240  7,877  8,258  Gross Profit32,598  29,955  26,797  26,516  Operating ExpensesResearch Development12,755  13,733  13,534  14,590  Selling General and Administrative34,686  29,382  26,403  24,358  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(14,843)(13,160)(13,140)(12,432)Income from Continuing OperationsTotal Other Income/Expenses Net77  103  220  292  Earnings Before Interest And Taxes(14,766)(13,057)(12,920)(12,140)Interest Expense201   -   -   -  Income Before Tax(14,967)(13,057)(12,920)(12,140)Income Tax Expense(17)317  314   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(14,950)(13,374)(13,234)(12,140)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   -   - ...
Click here to read the whole Article (external link)